The CARD study, a randomized, multicenter, open-label, phase 4 study involved 62 clinical sites across 13 European countries. CARD showed that cabazitaxel (Jevtana) offered a significantly improved radiographic progression-free survival and overall survival versus abiraterone (Zytiga) or enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer previously treated with docetaxel and the alternative androgen signaling-targeted inhibitor.

In this new analysis, reported in Lancet, of the data from CARD, researchers also demonstrated that Jevtana over both Zytiga and Xtandi improved a man’s quality of life (QoL). Jevtana was shown to improve pain response, delay the time to pain progression, and delay the development of a symptomatic skeletal event. Health-related quality of life was no worse with Jevtana compared with the anti-androgens, Zytiga, and Xtandi.

These findings support the use of cabazitaxel (Jevtana) for the treatment of metastatic castration-resistant prostate cancer.

This trial was supported by funding from Sanofi, the maker of cabazitaxel (Jevtana).

The abstract for this study is available by accessing this link